Almirall’s new AI deal with Absci; Jazz partners with Autifony; SAB raises $67M

Plus, Vit­to­ria rais­es $15 mil­lion, and a spin­out from Glas­gow and Ox­ford uni­ver­si­ties gets £4.3 mil­lion in seed fund­ing:

Almi­rall, Ab­sci part­ner on AI drug dis­cov­ery: The com­pa­nies said Tues­day that they’re work­ing to­geth­er to de­vel­op and com­mer­cial­ize treat­ments us­ing AI for two der­ma­to­log­i­cal con­di­tions. The Span­ish drug­mak­er will pay Ab­sci up to $650 mil­lion, which in­cludes up­front fees and post-ap­proval mile­stones. Ab­sci’s stock was up about 5% on Tues­day morn­ing, while Almi­rall’s shares gained about 3%. — Jaimy Lee

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.